News and Trends 6 Jul 2015
ElsaLys Biotech grabs MABLife’s dual-acting antibody to treat cancer
French ElsaLys Biotech just acquired MABLife’s anti-CD160 antibody. Originally developed for the treatment of vascular eye diseases, the antibody also has the potential to be applied for tumor therapy. It…